Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03315039 · ClinicalTrials.gov registry record · Phase 1
Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
A Phase 1 study, sponsored by Moleculin Biotech.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03315039: Completed Phase 1 study, sponsored by Moleculin Biotech.
NCT03315039 is a Phase 1 study that has completed, run by Moleculin Biotech. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03315039, a Phase 1 study, has completed, sponsored by Moleculin Biotech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a multi-center, open-label, dose escalation study that will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of liposomal annamycin as a single agent for the treatment of subjects with AML that is refractory to or relapsed after standard induction therapy
Primary Outcome
Number of patients with a dose-limiting toxicity (DLT) at each dose evaluated
Interventions
- DRUG Liposomal Annamycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-03-28 |
| Est. Completion | 2020-06-20 |
| Phase | Phase 1 |
What the finished NCT03315039 record still lists
NCT03315039 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which Liposomal Annamycin is the first listed.
NCT03315039 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03315039 about?
NCT03315039 is a clinical study titled "Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)". This is a multi-center, open-label, dose escalation study that will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of liposomal annamycin as a single agent for the treatment of subjects with AML that is refractory to or relapsed after standard induction therapy
What is the current status of trial NCT03315039?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2018-03-28. Estimated completion is 2020-06-20.
What interventions are being tested in trial NCT03315039?
The interventions under investigation include: Liposomal Annamycin (DRUG).
Who is sponsoring clinical trial NCT03315039?
This trial is sponsored by Moleculin Biotech, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03315039's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI